1 / 16

Rituximab in children with B-NHL on top of BFM95 protocol

Rituximab in children with B-NHL on top of BFM95 protocol. Paediatric Oncology and Haematology Research Institute N.N.Blokhin Russian Cancer Research Center Moscow. Т.Т. Valiev , A.V.Popa , G.L.Mentkevich. Results of multicenter studies on III/IV stages childhood B-NHL.

maia
Download Presentation

Rituximab in children with B-NHL on top of BFM95 protocol

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Rituximab in children with B-NHL on top of BFM95 protocol Paediatric Oncology and Haematology Research Institute N.N.Blokhin Russian Cancer Research Center Moscow Т.Т.Valiev, A.V.Popa, G.L.Mentkevich

  2. Results of multicenter studies on III/IV stages childhood B-NHL

  3. EFS in pediatric pts with B-NHL in Russia (2004) Вероятность Р=0,035 годы • Е.В.Самочатова, Н.В.Мякова и др. Гематология и трансфузиология»,2004,№1,с.3;

  4. Literature data are limited • 3-year EFS in children with B-NHL III/IV stages treated by FAB/LMB96 (R+) - 95% FAB/LMB96 (R-) – 84% • Goldman , ASH, Abstract No 2702, 2011

  5. Overall response rate 41% • Rituximab toxicity (grade III/IV) -General condition 15% -Fatigue 13% -ALT/AST 8% -Anaphylaxis 7% -Infection 3%

  6. B-NHL-BFM 95 protocol modification(Italian experience)(A.Rosolen, M.Pillon, L.Mussolin 2012)

  7. Modified B-NHL BFM95 protocol(rituximab regimen) 2007-2010 4 risk group AA BB CC AA BB CC 3 risk group АА ВВ СС АА ВВ

  8. Patients characteristics

  9. Results of modified B-NHL BFM95 protocol(rituximab regimen) EFS= 94,4+/-4,3% R+ (n=28) (median73,7+/-4,3 мo) EFS= 74,8+/-9,7% R- (n=25) (median 119,8+/-8,7 мo)

  10. EFS in group with M1 – 91,9% • EFS in group without M1 – 92,5%

  11. Modified B-NHL BFM95(rituximab regimen, block reduction) 2010-… 4 risk group AA BB CC AA BB 3 risk group АА ВВ СС АА ВВ

  12. Comparative analysis of block reduction and standard block therapy with rituximab

  13. Treatment failure for B-NHL BFM95 protocol (rituximab regimen)

  14. Treatment toxicity for B-NHL BFM95 protocol (rituximab regimen)

  15. Conclusions • Rituximab with B-NHL BFM95 protocol as a first-line treatment in children with B-NHL(unfavorable stages and risk groups) increased EFS significantly • Toxicity profile of rituximab regimen was comparable with standard B-NHL BFM95 protocol • It is possible to reduce block number for pts with B-NHL R4 with early complete response from six to five

  16. Thank Youfor attention!

More Related